Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Complementary and Alternative Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Association of traditional Chinese medicine therapy and the risk of dementia in patients with hypertension: a nationwide population-based cohort study

BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201717:178

https://doi.org/10.1186/s12906-017-1677-4

Received: 10 October 2016

Accepted: 11 March 2017

Published: 29 March 2017

Abstract

Background

Patients with hypertension (HTN) reportedly have a higher risk of developing dementia. However, it remains unclear if use of Traditional Chinese Medicine (TCM), the most common form of complementary and alternative medicine, can help lower the risk of dementia for these patients. So the aim of the study was to investigate the effects of TCM on dementia risk among patients with hypertension.

Methods

This longitudinal cohort study used the Taiwanese National Health Insurance Research Database (NHIRD) to identify 143,382 newly diagnosed hypertension patients aged 20–90 years who received treatment between 1998 and 2007. Among them, 52,365 (36.52%) had received TCM after the onset of hypertension (TCM users), and the remaining 91,017 patients (63.48%) were designated as a control group (non-TCM users). All enrollees were followed until the end of 2012 to record the incidence of dementia. A Cox proportional hazards regression model was used to compute the hazard ratio (HR) of dementia in patients who received TCM.

Results

During the 15-year follow-up, 3933 TCM users and 10,316 non-TCM users developed dementia, representing an incidence rate of 8.41 and 11.55%, respectively, per 1000 person-years. TCM users had a significantly reduced risk of dementia compared to non-TCM users (adjusted HR = 0.76; 95% confidence interval [CI] = 0.74–0.81). The predominant effect was observed among those treated with TCM longer than 180 days (adjusted HR = 0.65; 95% CI = 0.62–0.69). Among the commonly used TCM products, Tian-Ma-Gou-Teng-Yin, Dan-Shen (Radix Salviae Miltiorrhizae), Chuan-Niu-Xi (Radix Cyathulae), Ge-Gen (Radix Puerariae), Jia-Wei-Xiao-Yao-San, and Jue-Ming-Zi (Semen Cassiae) were significantly associated with a lower risk of dementia.

Conclusions

Results from this population-based study support the effects of TCM on reducing dementia risk, which may provide a reference for dementia prevention strategies.

Keywords

Cohort studyDementiaTraditional Chinese medicineHypertension

Background

Dementia is characterized by impairment of cognition involving learning, memory, language, executive function, complex attention, perceptual-motor skills, and social cognition [1]. In 2015, 46.8 million people worldwide had dementia, and 9.9 million new cases are reported every year [2]. The occurrence and irreversibility of this illness pose a heavy burden on society and families. The estimated global costs of dementia care have increased from $604 billion in 2010 to $818 billion in 2015 (in US dollars), representing an increase of 35.4% [2]. Although acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists have been effective for enabling patients to maintain global function, there is currently no treatment to halt or reverse the degenerative progression of dementia [3].

Nowadays, Traditional Chinese Medicine (TCM) has become increasingly popular as an alternative treatment for several critical illnesses, such as diabetes mellitus [4], atopic dermatitis [5], cancer [6], fractures [7], or vertigo [8]. Although previous research has indicated that several TCM herbs have shown potential benefits for dementia intervention [9], the evidence of long-term effects of TCM on dementia risk is still limited.

Hypertension (HTN), a common chronic disorder, is a critical challenge in global public health. It is noteworthy that HTN has been consistently associated with an increased risk of dementia in most cross-sectional and longitudinal cohort studies, and appears to be more relevant when it presents in middle age rather than later in life [1012]. Results of previous studies have demonstrated that TCM can lower blood pressure and modify vascular risk factors in patients with HTN [13, 14], which may be related to dementia [15, 16]. However, to our knowledge, there is a paucity of information on the benefit of TCM for dementia risk, in particular for subjects with HTN. To address this concern, we studied claims data from the Taiwanese National Health Insurance Research Database (NHIRD) to determine the effect of TCM services on subsequent risk of dementia among HTN individuals. The results of this study may serve as a reference for further pharmacological studies and clinical trials.

Methods

Data source

This retrospective cohort study used Taiwan’s Longitudinal Health Insurance Database (LHID), which is maintained by the National Health Insurance Administration and available to Taiwanese researchers. In 1995, Taiwan launched a single-payer national health insurance program designed to remove financial barriers to medical care for all legal residents. As of 2010, over 99% of Taiwan’s population have been enrolled in this program [17]. The LHID, a sub-dataset of the NHI program, is made up of data from 1 million randomly sampled Taiwanese citizens alive in 2000. We collected all medical records available for these individuals from 1997 to 2012. Because a multistage stratified systematic sampling method was used, no statistically significant differences in sex or age existed between the 1 million insured individuals and the general population [17]. This database contains all NHI enrollment files, claims data, and the registry for prescription drugs, which thus provides comprehensive pharmacological utilization information for subjects covered by the insurance program. To date, more than 300 published papers have utilized this de-identified secondary data.

This study was conducted in accordance with the Helsinki Declaration, and it was also evaluated and approved by the local Institutional Review Board and Ethics Committee of Buddhist Dalin Tzu Chi Hospital, Taiwan (No. B10004021–1). Since the LHID files contain only de-identified secondary data, the review board waived the requirement for obtaining informed consent from the patients.

Study population

The participant selection method is shown in Fig. 1. All diagnoses in this insurance claims data were coded with the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM). With it, we identified patients 20 to 90 years of age with newly diagnosed HTN within the 1998–2007 time period (ICD-9-CM codes: 401–405) as the study cohort. To reduce concern about disease misclassification, we selected only those cases where at least three diagnoses were made during outpatient visits or cases where patients were admitted to a hospital with a primary diagnosis of HTN within the observational period (n = 145,734). Patients with HTN who were followed for less than 3 months or who had a prior diagnosis of dementia before the first-time HTN diagnosis were excluded (n = 2352). Patients with dementia were identified if they had at least two treatment claims for dementia during outpatient visits or if they had been hospitalized with dementia for ICD-9-CM codes 290, 294, or 331. A final group of 143,382 subjects with HTN were included in the data analysis.
Fig. 1

A flowchart about the selection and follow-up of study subjects

In Taiwan, only certified Chinese medicine physicians are entitled to provide TCM services. We used the frequency of visits for TCM to verify the TCM exposure of each study subject. HTN subjects who received TCM for more than 30 days were considered TCM users, whereas those treated for 30 days or less were considered non-TCM users [8]. The index date of the follow-up period for HTN subjects who were classified as non-TCM users was assigned to the date of the first HTN diagnosis, whereas the index date of follow-up period for HTN cases with TCM usage was assigned to the first date of the initiation of TCM services. The end date of the follow-up period for both groups was assigned as the date of the earliest of one of the following: a diagnosis of dementia, the date of withdrawal from the insurance program, or the date of December 31, 2012.

Demographic characteristics and comorbidity

Demographic characteristics considered in this study included age, gender, income for estimating insurance payment, the availability of TCM resources, and urbanization level of the subject’s residential area. The subjects’ monthly incomes were stratified into 3 levels: ≤ New Taiwan Dollar (NTD) 17,880, NTD 17,881–NTD 43,900, and ≥ NTD 43,901. Urbanization levels were divided into 3 strata: urban (levels 1–2), suburban (levels 3–4), and rural (levels 5–7) areas. Level 1 refers to the “most urbanized” and level 7 refers to the “least urbanized” communities [18]. The comorbid medical conditions, for each individual, were evaluated by using the Charlson-Deyo comorbidity index (CCI) [19]. This index is a widely used method of categorizing comorbidities of patients based on the ICD-9 diagnosis codes found in administrative data. In this study, only diagnoses given ahead of and in concurrence with the diagnosis of HTN were regarded as underlying comorbidities.

Statistical analysis

We used the chi-square test and Student’s t-test to examine the differences in demographic characteristics and comorbidities between subjects who received and those who did not receive TCM services. Thereafter, the Cox proportional hazards regression analysis was applied to compute the hazard ratio (HR) with 95% confidence intervals (CI) of dementia risk in association with TCM use. To test the robustness of the relationship between TCM use and dementia risk, we divided the TCM users into two subgroups: one group used TCM for 30 to 180 days, and the other group used TCM for more than 180 days. Furthermore, a stratified analysis by age and gender using Cox proportional hazards regression was also conducted to assess the relative risk of dementia among the subjects who received and did not receive TCM services. The proportional-hazards assumption was verified using plots of log (−log (survival function) vs log (time) and Schoenfeld residuals vs time. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA), at a P < 0.05 statistically significant level.

Results

We identified 143,382 patients with HTN during the period from 1998 to 2007. Of these, 52,365 subjects received TCM services and 91,017 subjects were classified as non-TCM users. Table 1 shows the basic characteristics of the two groups. Compared to the non-TCM users, HTN patients receiving TCM services were more likely to be female and younger, to have lower monthly incomes and tobacco use, to have higher CCI scores, and to reside in an urban area (all P < 0.01).
Table 1

Demographic data and selected comorbidities of the study subjects

Variables

Non-TCM users

TCM users

P-value

n = 91,017 (%)

n = 52,365 (%)

Age (yr)

  

<0.001

 ≤50

22,971 (25.2)

16,461(31.4)

 

 >50

68,046 (74.8)

35,904 (68.6)

 

Mean (SD)

59.74 (13.6)

57.19 (12.4)

<0.001

Gender

  

<0.001

 Female

40,794 (44.8)

29,597(56.5)

 

 Male

50,223(55.2)

22,768 (43.5)

 

Monthly income

  

<0.001

 Low

39,976(43.9)

21,506 (41.1)

 

 Median

46,352 (50.9)

28,123 (53.7)

 

 High

4689 (5.2)

2736 (5.2)

 

Residential area

  

<0.001

 Urban

49,720(54.6)

29,629 (56.6)

 

 Suburban

14,209(15.6)

8426 (16.1)

 

 Rural

27,088(29.8)

14,310 (27.3)

 

Tobacco use

  

0.002

 Yes

352 (0.4)

150 (0.3)

 

 No

90,665 (99.6)

52,215 (99.7)

 

CCI

  

<0.001

 Mean (SD)

3.50 (4.42)

4.23 (7.03)

 

TCM Traditional Chinese Medicine, SD, standard deviation; CCI Charlson-Deyo comorbidity index

Among the 143,382 HTN subjects, 14,249 first episodes of dementia occurred; 10,316 were reported among the non-TCM users and 3933 among the TCM users during the follow-up of 892,960.27 and 467,500.55 person-years (PYs), respectively. The incidence rate of dementia was lower among TCM users than among non-TCM users (8.41 vs 11.55, respectively, per 1000 PYs), with an adjusted HR of 0.76 (95% CI = 0.74–0.81) (Table 2). Of note, using TCM services for more than 180 days was associated with a 35% decreased risk of dementia among HTN patients (95% CI = 0.62–0.69).
Table 2

Risk of dementia for HTN subjects with and without TCM

Patient group

Event

PYs

Incidence

Crude HR (95% CI)

Adjusted HRa (95% CI)

Non-TCM users

10,316

892,960.27

11.55

1

1

TCM users

3933

467,500.55

8.41

0.73(0.71–0.76)

0.76 (0.74–0.81)

TCM use within

30–180 days

2706

289,829.43

9.34

0.82 (0.78–0.85)

0.86 (0.82–0.90)

TCM use for more than 180 days

1277

177,671.13

6.91

0.60 (0.57–0.64)

0.65 (0.62–0.69)

TCM Traditional Chinese Medicine, PYs per 1000 person-years, HR hazard ratio, CI confidence interval

aModel adjusted for age, gender, urbanization level, monthly income, and CCI scores

As for the sex-specific risk of dementia, we discovered that both female and male HTN patients receiving TCM services had a significantly decreased risk of dementia, with an adjusted HR of 0.71 (95% CI = 0.68–0.74) and 0.84 (95% CI = 0.81–0.91), respectively (Table 3). Additionally, because a significant interaction of age and sex in relation to TCM use occurred, we further performed a stratified analysis by age and sex to determine the effect of TCM on dementia risk. In general, use of TCM was associated with a lower risk of dementia, irrespective of sex. The multivariable stratified analysis verified significant associations of dementia risk with TCM use among male subjects with HTN aged ≤50 years (adjusted HR = 0.72; 95% CI = 0.57–0.89); for female subjects, the more beneficial effect of TCM on the risk of dementia was noted for those older than 50 years (adjusted HR = 0.70; 95% CI = 0.67–0.75) (Table 3).
Table 3

Incidence and dementia risk for HTN patients with and without TCM in the stratification of sex and age

Variables

Non-TCM users

TCM users

Crude HR (95% CI)

Adjusted HR

(95% CI)

Case

PYs

Incidence

Case

PYs

Incidence

Female

  ≤ 50 yr

148

81,138.18

1.82

111

79,715.46

1.39

0.77

(0.60–0.98)

0.76a

(0.59-0.97)

  > 50 yr

4949

320,644.53

15.43

2104

188,214.45

11.18

0.73

(0.70–0.77)

0.70a

(0.67-0.75)

 All

5097

401,782.71

12.69

2215

267,926.61

8.27

0.66

(0.63–0.69)

0.71b

(0.68-0.74)

Male

  ≤ 50 yr

307

139,732.62

2.20

107

65,359.01

1.64

0.75

(0.59–0.93)

0.72a

(0.57-0.89)

  > 50 yr

4912

351,444.93

13.98

1611

134,211.63

12.00

0.85

(0.81–0.91)

0.87a

(0.83-0.92)

 All

5219

491,177.56

10.63

1718

199,570.64

8.61

0.81

(0.77–0.86)

0.84b

(0.81-0.91)

TCM Traditional Chinese Medicine, PYs person-years, HR hazard ratio, CI confidence interval

aModel adjusted for urbanization level, monthly income, and CCI scores

bModel adjusted for age, urbanization level, monthly income, and CCI scores

The most commonly prescribed TCMs for patients with HTN are summarized in Table 4. Of the 15 most common TCMs, 6 were herbal formulas and 9 were single herbs. Tian-Ma-Gou-Teng-Yin (TMGTY) was the most used herbal formula, followed by Dan-Shen and Gou-Teng-San. Of these TCMs, Tian-Ma-Gou-Teng-Yin, Dan-Shen, Chuan-Niu-Xi, Ge-Gen, Jia-Wei-Xiao-Yao-San, and Jue-Ming-Zi were found to be significantly related to a lower risk of dementia (Table 5).
Table 4

Top 15 commonly prescribed TCMs for treating HTN during study period

TCM name

Ingredients or generic name

Functions in TCM

Frequency of prescriptions

N = 503,567 (%)

Average daily does (g)

Average duration of prescription (day)

Tian-Ma-Gou-

Teng-Yin

Rhizoma Gastrodiae; Ramulus Uncariae Cum Uncis; Concha Haliotidis; Fructus Gardeniae Jasminoidis; Radix Scutellariae Baicalensis; Radix Cyathulae; Cortex Eucommiae Ulmoidis; Herba Leonuri; Herba Taxilli; Caulis Polygoni Multiflori; Sclerotium Poriae Cocos

Calms the Liver, Extinguishes Wind, Clears Heat, Invigorates the Blood, Tonifies the Liver and Kidneys

24,823(4.9)

7.2

11.0

Dan-Shen

Radix Salviae Miltiorrhizae

Activates the Blood and dispels Blood Stasis, Cools the Blood and reduces abscesses, Nourishes the Blood and calms the Spirit

13,197(2.6)

3.0

11.7

Gou-Teng-San

Ramulus Uncariae Cum Uncis; Radix Ginseng;

Sclerotium Poriae Cocos; Sclerotium Poriae Curcum; Radicem Pini; Radix Ophiopogonis;

Pericarpium Citri Reticulatae;

Rhizoma Pinelliae Preparatum; Radix Saposhnikoviae

Flos Chrysanthemi; Gypsum Fibrosum; Rhizoma Zingiberis Recens; Radix Glycyrrhizae

Clears Heat from the Liver channel, Descends Liver Yang, Extinguishes Liver Wind, Transforms Phlegm, Strengthens the Spleen, Enriches fluids

10,043(2.0)

7.4

9.5

Gou-Teng

Ramulus Uncariae Cum Uncis

Extinguishes Wind and alleviates spasms, Drains Liver Heat and pacifies Liver Yang, Releases the Exterior

8957(1.8)

2.8

11.2

Xia-Ku-Cao

Spica Prunellae

Clears Liver Fire and brightens the eyes, Clears Hot Phlegm and dissipates nodules

8153(1.6)

2.2

11.0

Zhi-Bai-Di-

Huang-Wan

Radix Rehmanniae Preparata; Fructus Corni Officinalis; Cortex Moutan; Rhizoma Dioscoreae Oppositae; Sclerotium Poriae Cocos; Rhizoma Alismatis Orientalis; Rhizoma Anemarrhenae Asphodeloidis; Cortex Phellodendri Chinensis

Enriches Yin, Nourishes the Essence of the Liver and Kidneys, Reduces Deficiency Fire

6123(1.2)

5.1

11.9

Da-Huang

Radix et Rhizoma Rhei

Purges Heat, Loosens the bowels, Promotes Blood circulation, and removes Blood Stasis

5932(1.2)

1.1

11.4

Xue-Fu-Zhu-

Yu-Tang

Semen Pruni Persicae; Flos Carthami Tinctorii; Rhizoma Ligustici Chuanxiong; Radix Angelicae Sinensis; Radix Cyathulae; Fructus Aurantii; Radix Paeoniae Rubra; Radix Platycodi Grandiflori; Radix Bupleuri Chinensis; Radix Rehmanniae Glutinosae; Radix Glycyrrhizae Uralensis

Invigorates the Blood, Dispels Blood Stasis, Spreads Liver Qi, Unblocks the channels, Stops pain

5758(1.1)

6.6

11.5

Chuan-Niu-Xi

Radix Cyathulae

Invigorates the Blood, Dispels Blood Stagnation, Promotes Urination and Drains Damp, Tonifies Liver and Kidney, Strengthens Tendon

5660(1.1)

2.3

12.4

Ge-Gen

Radix Puerariae

Dispels pathogenic factors from the superficial muscles to relieve fever, Promotes the production of body Fluid, Invigorates the Spleen Yang to stop diarrhea

5329(1.0)

1.5

10.7

Qi-Ju-Di-

Huang-Wan

Radix Rehmanniae Preparata; Fructus Corni Officinalis; Rhizoma Dioscoreae Oppositae; Rhizoma Alismatis Orientalis; Sclerotium Poriae Cocos; Cortex Moutan Radicis; Fructus Lycii Chinensis; Flos Chrysanthemi Morifolii

Enriches Yin, Nourishes the essence of the Liver and Kidneys, Brightens eyes, improves vision, Enriches Blood

4286(0.9)

5.7

13.8

San-Qi

Radix Notoginseng

Arrests bleeding, Resolves Blood Stasis, Promotes the circulation of Blood

4254(0.8)

3.3

10.7

Tian-Ma

Rhizoma Gastrodiae

Stops Wind to relieve convulsion, Soothes the Liver, and suppresses hyperactive Liver Yang

4192(0.8)

1.6

11.1

Jia-Wei-Xiao-

Yao-San

Radix Bupleuri Chinensis; Radix Angelicae Sinensis; Radix Paeoniae Lactiflorae; Rhizoma Atractylodis Macrocephalae; Sclerotium Poriae Cocos; Radix Glycyrrhizae Uralensis; Cortex Moutan Radicis; Fructus Gardeniae Jasminoidis; Herba Menthae Haplocalycis; Rhizoma Zingiberis Recens

Pacifies the Liver, Spreads Liver Qi, Strengthens the Spleen, Nourishes the Blood and Yin, Regulates menstruation, Sedates the Heart, Clears Heat

3984(0.8)

7.5

13.3

Jue-Ming-Zi

Semen Cassiae

Clears Liver Heat, Improves eyesight, Moistens the Intestines to relieve constipation

3949(0.8)

2.1

10.2

Table 5

Risk of dementia in relation to the top 15 commonly used TCMs

TCM name

Crude HR (95% CI)

Adjusted HRj (95% CI)

Tian-Ma-Gou-Teng-Yin a,c,d,e,f,g,h,i

0.77 (0.68–0.86)

0.82 (0.76–0.95)k

Dan-Shen a,d,e,f,g,h,i

0.71 (0.61–0.83)

0.80 (0.69–0.92)k

Gou-Teng-San

0.78 (0.65–0.92)

0.90 (0.74–1.07)

Gou-Teng

0.75 (0.61–0.90)

0.89 (0.75–1.08)

Xia-Ku-Cao

0.70 (0.56–0.86)

0.79 (0.60–1.02)

Zhi-Bai-Di-Huang-Wan

0.88 (0.68–1.10)

0.97 (0.76–1.23)

Da-Huang

0.89 (0.67–1.15)

0.92 (0.70–1.20)

Xue-Fu-Zhu-Yu-Tang

0.82 (0.67–0.99)

0.91 (0.75–1.21)

Chuan-Niu-Xi e,f,i

0.73 (0.58–0.92)

0.79 (0.62–0.98)k

Ge-Gen a,b,f,g,h,i

0.62 (0.43–0.79)

0.65 (0.52–0.83)k

Qi-Ju-Di-Huang-Wan

0.87 (0.68–1.12)

0.85 (0.66–1.09)

San-Qi

0.85 (0.66–1.10)

0.89 (0.69–1.19)

Tian-Ma

0.98 (0.79–1.22)

0.96 (0.77–1.19)

Jia-Wei-Xiao-Yao-San a,b,i

0.70 (0.54–0.91)

0.79 (0.64–0.98)k

Jue-Ming-Zi a,e,h,i

0.57 (0.41–0.80)

0.68 (0.49–0.96)k

HR hazard ratio, CI confidence interval

Potential therapeutic effects of the most promising TCMs:

aReduces β-amyloid protein or its toxicity

bReduces Tau protein or its abnormal phosphorylation

cInhibits NMDA receptor

dInhibits acetylcholinesterase

eAnti-inflammatory

fAntioxidant activity

gAnti-apoptosis

hNeuroprotective effects

iMedicinal benefits in vascular risk factors

jModel adjusted for age, gender, urbanization level, monthly income, and CCI scores

kPromising TCMs that were significantly related to the lower risk of dementia

Discussion

To our knowledge, this is the first population-based cohort study to address the influence of TCM on the risk of dementia among patients with HTN. The study results provide more robust findings about the effects of TCM in this patient population, and may allow clinicians to choose the most appropriate treatment for HTN individuals.

Results of this 15-year follow-up study showed that subjects with HTN who received TCM services exhibited a 24% reduced risk of dementia as compared to those who did not receive TCM services. In addition, the use of TCM services for more than 180 days was associated with a 35% decreased risk of developing dementia. Furthermore, the stratified analysis supported that the TCM intervention significantly reduced the risk of dementia in females more than for males, with adjusted HR of 0.71 and 0.84, respectively. One contributing factor might be that Taiwanese females often exhibit better adherence behaviors than males [20], thus preventing their disease from worsening.

The findings of this study also showed that TCM services may result in fewer effects on females younger than 50 years of age compared to males of similar age. We speculate that younger women may benefit from higher estrogen levels, which could decrease serum low-density lipoprotein-cholesterol (LDL-C) levels and curb coronary thrombosis and atherosclerosis by regulating vascular smooth muscle and endothelial cells [21]. This biochemical benefit may lessen the corresponding effect of TCM services. Taken together, these results clearly demonstrate that earlier and longer use of TCM among HTN patients is associated with reduction of dementia risk.

The two principal types of dementia, Alzheimer’s disease (AD) and vascular dementia (VaD), account for about 70 and 15% of cases of dementia, respectively [22]. Reducing the amount of beta-amyloid protein (Aβ) and tau protein in the brain and modulating Aβ toxicity, including inflammatory response, oxidative stress, and neuronal apoptosis, have been considered the most promising therapeutic strategies available for controlling the progression of dementia [23, 24].

In our study, six TCMs were found to be significantly related to a lower risk of dementia, and these have been reported to exert most of the neuroprotective activities mentioned above. Additionally, most of these TCMs have shown medicinal benefits in reducing vascular risk factors of AD and VaD, and thus they may also help reduce the risk of dementia [15, 16]. The possible pharmacological mechanisms of the most common TCMs for the treatment of patients with HTN are summarized in Tables 4 and 5.

We discovered that the most commonly prescribed herbal formula, Tian-Ma-Gou-Teng-Yin (TMGTY), was used in TCM for relieving symptoms related to high blood pressure, such as headaches and dizziness. Results of previous studies have shown that TMGTY has significant effects on a variety of HTN-caused cardiovascular diseases [14]. Recent scientific evidence has also demonstrated that TMGTY provides neuroprotective effects for patients with Parkinson’s disease [25]. TMGTY has also been found to inhibit the NMDA receptor. This leads to a reduction in necrosis and apoptosis in neuronal cells through a variety of pharmacological effects, including anti-inflammatory, antioxidative, and anti-apoptotic activities [26]. Moreover, the components of TMGTY could decrease the activity of acetylcholinesterase and show potent anti-aggregation effects on Aβ proteins [27, 28].

Dan-Shen (Radix Salviae Miltiorrhizae) and Ge-Gen (Radix Puerariae) are two herbs frequently used for the treatment of angina and other cardiac symptoms in TCM. Recent studies have demonstrated their cardioprotective and anti-atherosclerosis effects. Results of pharmacological studies suggest that these herbs can control high blood pressure, lower serum lipids, and improve microcirculation [29]. Dan-Shen demonstrated neuroprotective effects [29], including inhibition of Aβ aggregation, oligomerization, and fibril formation through upregulation of activity of alpha-secretases [30]. Dan-Shen also acts as an acetylcholinesterase inhibitor [31], and it could improve age-related oxidative stress and inflammatory response [32], protect endothelial cells from hydrogen peroxide damage, and inhibit apoptosis [33]. Ge-Gen was found to show potential medicinal benefits in diabetes and cardiovascular and cerebrovascular diseases [34], and it could alleviate neurological deficits and improve learning and memory after ischemia/reperfusion-induced cerebral microcirculatory disturbances [35]. Recent studies have also demonstrated that Ge-Gen could inhibit Aβ plaque accumulation [36], suppress tau protein expression [37], and antagonize neuronal apoptosis induced by oxidative stress [38].

Chuan-Niu-Xi ( Radix Cyathulae) has demonstrated various beneficial pharmacological activities, including analgesic, immunostimulant, antitumor, anti-inflammatory, and antiaging effects. Its use removes blood stasis, restores menstrual flow, and induces diuresis for treating stranguria. It also has antioxidant qualities [39].

Jia-Wei-Xiao-Yao-San is widely used to relieve emotional and neuropsychological disorders such as depression, stress [40], and dyskinesia in patients with schizophrenia [41]. Researchers have also shown that Jia-Wei-Xiao-Yao-San can reduce tremors of antipsychotic-induced parkinsonism [42], relieve migraine headache [43], and improve the survival rate of type 2 diabetes patients with HTN [44]. Moreover, the components of Jia-Wei-Xiao-Yao-San can inhibit abnormal tau phosphorylation, suppress the release of Aβ peptides, and decrease beta-amyloid-induced neurotoxicity [45, 46].

Another TCM herb, Jue-Ming-Zi (Semen Cassiae) has shown neuroprotective effects in animal models of ischemic stroke and Parkinson’s disease [47]. Results of a recent study also demonstrated that this herb can ameliorate amyloid-β-induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3β pathways [48]. In our study, all of the previously mentioned TCM agents relieved the symptoms of HTN and decreased the risk of developing dementia.

Although our study is the first to recently investigate the effect of use of TCM on the risk of dementia among subjects with HTN, there are some important limitations to consider. First, identification of use of TCM and outcomes were based on three categories in the ICD-9-CM, and inaccurate diagnosis may have occurred. To minimize this error, we only selected subjects with either HTN or dementia after they were recorded as having at least three outpatient visits reporting consistent diagnoses or one inpatient admission for HTN. It should also be noted that the NHI of Taiwan randomly samples claims from hospitals, interviews patients, and reviews medical charts to verify the accuracy of medical records. Second, we could not account for other confounding factors, such as the use of tobacco and alcohol, physical activity, dietary preferences, social network relationships, coping strategies, or educational level, which were unavailable from the claims data. Further studies controlling for those untested factors are recommended to assess whether the present findings are replicable among other demographically and geographically diverse groups. Third, we were unable to contact the enrolled patients directly about the use of Chinese herbs due to the anonymity of identification numbers in the database. Even so, we were still able to demonstrate the benefit from TCM use. Nearly 95% of dosing frequencies in Chinese herbs are typically only used for one week in clinical practice, so those who continued to receive the same prescriptions for a longer period were therefore likely to have used the prescribed medication [49]. Fourth, the NHI program only pays for TCMs prescribed by Chinese medicine physicians, not over-the-counter TCMs. Therefore, the use of TCM may be underestimated. However, the NHI covers TCM prescriptions (the concentrated herbal powder) manufactured by GMP-certified pharmaceutical companies in Taiwan. Within the NHI program, the copayment for visiting a TCM clinic is only approximately 10 USD, which may greatly enhance the accessibility to TCM services. Fifth, findings from any retrospective cohort study are generally less sound than these from randomized trials because cohort study designs are subject to various biases related to uncontrolled confounding effects. Despite our careful attention to the study design, employing adequate control of confounding factors, unpredictable biases could still remain if they stem from unmeasured or unknown confounders. Notwithstanding these limitations, the strengths of this study must also be acknowledged and these included the immediate availability of data, the comprehensiveness of the database, and the statistical power derived from the samples’ large sizes. In addition, this retrospective 15-year cohort study allowed us to examine in detail the association of TCM usage with the subsequent risk of dementia, and the corresponding findings could serve as a reference for future treatments.

Conclusions

The results of this population-based, retrospective cohort study show that the use of TCM during treatment of HTN was associated with a 24% lower risk of developing dementia compared to the risk among non-TCM users. TCM users had a significantly reduced risk of dementia compared to non-TCM users (adjusted HR = 0.76; 95% CI = 0.74–0.81). The predominant effect was observed among those treated with TCM longer than 180 days (adjusted HR = 0.65; 95% CI = 0.62–0.69). These findings could serve as a reference for healthcare providers, in helping to establish more effective therapeutic interventions to improve the prognosis of patients with HTN and prevent subsequent dementia.

Abbreviations

Aβ: 

beta-amyloid

AD

Alzheimer’s disease

CCI

Charlson-Deyo comorbidity index

CI

Confidence interval

GMP

Good Manufacturing Practice

HR

Hazard ratio

HTN

Hypertension

LHID

Longitudinal Health Insurance Database

NHI

National Health Insurance

NHIRD

National Health Insurance Research Database

NMDA

N-methyl-D-aspartate

NTD

New Taiwan Dollar

PYs

Per 1000 person-years

SD

Standard deviation

TCM

Traditional Chinese Medicine

TMGTY

Tian-Ma-Gou-Teng-Yin

USD

United States Dollar

VaD

Vascular dementia

Declarations

Acknowledgements

The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by the National Health Research Institutes, in Taiwan. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes. This research was supported by Dalin Tzuchi Hospital (Grants DTCRD103 (2)-E-05). KH Chen and MH Yeh contributed equally to this work. Both TY Tsai and CC Yeh were corresponding authors.

Funding

This study was supported by a research grant provided by Dalin Tzuchi Hospital (Grant No: DTCRD 103(2)-E-05). The funding agent plays no role in study design, data collection, and data analyses.

Authors’ contributions

KH Chen and MH Yeh were involved in the study design and drafted the manuscript. MC Lu contributed to data analysis and revised the manuscript. H Livneh and BC Chen contributed to the interpretation of data and provided comments on the final draft of the manuscript. IH Lin and MC Lu provided administrative support and comments on the manuscript drafts. TY Tsai and CC Yeh were responsible for the study conception, design, data analysis, and drafting of the manuscript. All authors read and approved the final manuscript.

Availability of data and materials

The dataset is available from Taiwan’s National Health Research Institutes (http://nhird.nhri.org.tw).

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All authors have read and agreed to all the contents for publication.

Ethics approval and consent to participate

This study was conducted in accordance with the Helsinki Declaration, and it was also evaluated and approved by the local Institutional Review Board and Ethics Committee of Buddhist Dalin Tzu Chi Hospital, Taiwan (No. B10004021–1).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Chinese Medicine, Dalin Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation
(2)
School of Post-Baccalaureate Chinese Medicine, Tzu Chi University
(3)
School of Chinese Medicine, China Medical University
(4)
Rehabilitation Counseling Program, Portland State University
(5)
Division of Allergy, Immunology and Rheumatology, Dalin Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation
(6)
School of Medicine, Tzu Chi University
(7)
Department of Medical Research, Dalin Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation
(8)
Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University
(9)
Department of Nursing, Tzu Chi University of Science and Technology

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: Author; 2013.View ArticleGoogle Scholar
  2. Alzheimer’s Disease International. World Alzheimer Report. In.; 2015.Google Scholar
  3. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–7.View ArticlePubMedGoogle Scholar
  4. Hsu PC, Tsai YT, Lai JN, Wu CT, Lin SK, Huang CY. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014;156:358–64.View ArticlePubMedGoogle Scholar
  5. Chen YC, Lin YH, Hu S, Chen HY. Characteristics of traditional Chinese medicine users and prescription analysis for pediatric atopic dermatitis: a population-based study. BMC Complement Altern Med. 2016;16:173.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Fleischer T, Chang TT, Chiang JH, Hsieh CY, Sun MF, Yen HR. Integration of Chinese herbal medicine therapy improves survival of patients with chronic lymphocytic leukemia: a nationwide population-based cohort study. Medicine. 2016;95:e3788.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Liao HH, Yeh CC, Lin CC, Chen BC, Yeh MH, Chang KM, et al. Prescription patterns of Chinese herbal products for patients with fractures in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015;173:11–9.View ArticlePubMedGoogle Scholar
  8. Tsai TY, Li CY, Livneh H, Lin IH, Lu MC, Yeh CC. Decreased risk of stroke in patients receiving traditional Chinese medicine for vertigo: a population-based cohort study. J Ethnopharmacol. 2016;184:138–43.View ArticlePubMedGoogle Scholar
  9. Lin Z, Gu J, Xiu J, Mi T, Dong J, Tiwari JK. Traditional chinese medicine for senile dementia. Evid Based Complement Alternat Med. 2012;2012:692621.PubMedGoogle Scholar
  10. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014;71:1218–27.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.View ArticlePubMedGoogle Scholar
  12. Freitag MH, Peila R, Masaki K, Petrovitch H, Ross GW, White LR, et al. Midlife pulse pressure and incidence of dementia: the honolulu-Asia aging study. Stroke 2006;37:33-7.Google Scholar
  13. Xiong X, Wang P, Zhang Y, Li X. Effects of traditional Chinese patent medicine on essential hypertension: a systematic review. Medicine. 2015;94:e442.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Zhang G, Yang G, Deng Y, Zhao X, Yang Y, Rao J, et al. Ameliorative effects of Xue-Fu-Zhu-Yu decoction. Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode BMC Complement Altern Med. 2016;16:56.Google Scholar
  15. Alonso A, Mosley Jr TH, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009;80:1194–201.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461–8.View ArticlePubMedPubMed CentralGoogle Scholar
  17. National Health Research Institute. Longitudinal Health Insurance Research Database. 2011.Google Scholar
  18. Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag. 2006;4:1–22.Google Scholar
  19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.View ArticlePubMedGoogle Scholar
  20. Shih CC, Liao CC, Su YC, Tsai CC, Lin JG. Gender differences in traditional Chinese medicine use among adults in Taiwan. PLoS One. 2012;7:e32540.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282:254–60.View ArticlePubMedGoogle Scholar
  22. Ritchie K, Lovestone S. The dementias. Lancet. 2002;360:1759–66.View ArticlePubMedGoogle Scholar
  23. Lloret A, Badia MC, Giraldo E, Ermak G, Alonso MD, Pallardo FV, et al. Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis. 2011;27:701–9.PubMedPubMed CentralGoogle Scholar
  24. Xian YF, Mao QQ, Wu JC, Su ZR, Chen JN, Lai XP, et al. Isorhynchophylline treatment improves the amyloid-beta-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation. J Alzheimers Dis. 2014;39:331–46.PubMedGoogle Scholar
  25. Liu LF, Song JX, Lu JH, Huang YY, Zeng Y, Chen LL, et al. Tianma Gouteng Yin, a traditional Chinese medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson's disease. Sci Rep. 2015;5:16862.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Chik SC, Or TC, Luo D, Yang CL, Lau AS. Pharmacological effects of active compounds on neurodegenerative disease with gastrodia and uncaria decoction, a commonly used poststroke decoction. ScientificWorldJournal. 2013;2013:896873.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Huang GB, Zhao T, Muna SS, Jin HM, Park JI, Jo KS, et al. Therapeutic potential of Gastrodia elata Blume for the treatment of Alzheimer's disease. Neural Regen Res. 2013;8:1061–70.PubMedPubMed CentralGoogle Scholar
  28. Fujiwara H, Iwasaki K, Furukawa K, Seki T, He M, Maruyama M, et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's beta-amyloid proteins. J Neurosci Res. 2006;84:427–33.View ArticlePubMedGoogle Scholar
  29. Tam WY, Chook P, Qiao M, Chan LT, Chan TY, Poon YK, et al. The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients. J Altern Complement Med. 2009;15:415–21.View ArticlePubMedGoogle Scholar
  30. Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, et al. Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett. 2009;452:90–5.View ArticlePubMedGoogle Scholar
  31. Zhou Y, Li W, Xu L, Chen L. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ Toxicol Pharmacol. 2011;31:443–52.View ArticlePubMedGoogle Scholar
  32. Park CH, Kim DH, Park MH, Kim MK, Kim ND, Kim CM, et al. Chinese prescription kangen-karyu and salviae miltiorrhizae radix improve age-related oxidative stress and inflammatory response through the PI3K/Akt or MAPK pathways. Am J Chin Med. 2014;42:987–1005.View ArticlePubMedGoogle Scholar
  33. Yang GD, Zhang H, Lin R, Wang WR, Shi XL, Liu Y, et al. Down-regulation of CD40 gene expression and inhibition of apoptosis with Danshensu in endothelial cells. Basic Clin Pharmacol Toxicol. 2009;104:87–92.View ArticlePubMedGoogle Scholar
  34. Wong KH, Li GQ, Li KM, Razmovski-Naumovski V, Chan K. Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J Ethnopharmacol. 2011;134:584–607.View ArticlePubMedGoogle Scholar
  35. Sun K, Fan J, Han J. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. Acta Pharm Sin B. 2015;5:8–24.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Dong XH, Gao WJ, Kong WN, Xie HL, Peng Y, Shao TM, et al. Neuroprotective effect of the active components of three Chinese herbs on brain iron load in a mouse model of Alzheimer's disease. Exp Ther Med. 2015;9:1319–27.PubMedPubMed CentralGoogle Scholar
  37. Anukulthanakorn K, Parhar IS, Jaroenporn S, Kitahashi T, Watanbe G, Malaivijitnond S. Neurotherapeutic effects of pueraria mirifica extract in early- and late-stage cognitive impaired rats. Phytother Res. 2016;30:929–39.View ArticlePubMedGoogle Scholar
  38. Zhang H, Liu Y, Lao M, Ma Z, Yi X. Puerarin protects Alzheimer’s disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol. 2011;46:30–7.View ArticlePubMedGoogle Scholar
  39. Han X, Shen S, Liu T, Du X, Cao X, Feng H, et al. Characterization and antioxidant activities of the polysaccharides from radix cyathulae officinalis kuan. Int J Biol Macromol. 2015;72:544–52.View ArticlePubMedGoogle Scholar
  40. Tanaka M, Satou T, Koike K. Anxiolytic-like effect of Shigyakusan extract with low side effects in mice. J Nat Med. 2013;67:862–6.View ArticlePubMedGoogle Scholar
  41. Lee JG, Shin BS, Lee YC, Park SW, Kim YH. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Psychiatry Clin Neurosci. 2007;61:509–14.View ArticlePubMedGoogle Scholar
  42. Ishikawa T, Funahashi T, Kudo J. Effectiveness of the Kampo kami-shoyo-san (TJ-24) for tremor of antipsychotic-induced parkinsonism. Psychiatry Clin Neurosci. 2000;54:579–82.View ArticlePubMedGoogle Scholar
  43. Chang YY, Tsai YT, Lai JN, Yeh CH, Lin SK. The traditional Chinese medicine prescription patterns for migraine patients in Taiwan: a population-based study. J Ethnopharmacol. 2014;151:1209–17.View ArticlePubMedGoogle Scholar
  44. Lin YJ, Ho TJ, Yeh YC, Cheng CF, Shiao YT, Wang CB, et al. Chinese herbal medicine treatment improves the overall survival rate of individuals with hypertension among type 2 diabetes patients and modulates in vitro smooth muscle cell contractility. PLoS One. 2015;10:e0145109.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Lee TH, Park SH, You MH, Lim JH, Min SH, Kim BM: A potential therapeutic effect of Saikosaponin C as a novel dual-target anti-Alzheimer agent. J Neurochem 2015. [Epub ahead of print].Google Scholar
  46. Zhang Z, Zhao R, Qi J, Wen S, Tang Y, Wang D. Inhibition of glycogen synthase kinase-3beta by angelica sinensis extract decreases beta-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons. J Neurosci Res. 2011;89:437–47.View ArticlePubMedGoogle Scholar
  47. Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ, et al. Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson’s disease models. Food Chem Toxicol. 2010;48:2037–44.View ArticlePubMedGoogle Scholar
  48. Yi JH, Park HJ, Lee S, Jung JW, Kim BC, Lee YC, et al. Cassia obtusifolia seed ameliorates amyloid beta-induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3beta pathways. J Ethnopharmacol. 2016;178:50–7.View ArticlePubMedGoogle Scholar
  49. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102:179–86.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement